Paper Details

  1. Home
  2. Paper Details

Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis.

Author: BahrDaun, FriedmanJoseph H, JohnsonAnn, MeltzerHerbert Y, MillsRoger, RevellStephen, WilliamsHilde

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Pimavanserin, a selective 5-HT(2A) inverse agonist, was found to be well-tolerated and may be an effective treatment for psychosis in patients with Parkinson's disease. Pimavanserin did not worsen motor function or cause sedation or hypotension.
Paper Details　
Original Abstract of the Article :
Psychotic symptoms occur in up to 40% of patients with Parkinson's disease (PD). Clozapine and quetiapine, two atypical antipsychotic drugs, at doses markedly lower than those effective in schizophrenia, which, nevertheless, still cause sedation, hypotension, and other side effects, are widely used ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3055369/

データ提供：米国国立医学図書館（NLM）

Pimavanserin for Parkinson's Disease Psychosis: A New Oasis in the Desert of Mental Health

The desert of Parkinson's disease can be a challenging landscape, with psychosis often adding to the burden of symptoms. This research explores the potential of [pimavanserin], a new drug that selectively targets the [serotonin (5-HT(2A)) receptor], as a treatment for [Parkinson's disease psychosis (PDP)]. The study found that [pimavanserin] was well-tolerated and showed promise in reducing psychotic symptoms in patients with [PDP], offering a potential oasis of relief for those struggling with this debilitating condition. It's like discovering a hidden spring in the desert, offering a source of healing and restoration for those seeking relief from the mental fog of psychosis.

A New Hope for Parkinson's Disease Psychosis: Pimavanserin Shows Promise

This research suggests that [pimavanserin] may offer a new path to treatment for [PDP], targeting the [serotonin (5-HT(2A)) receptor] and potentially providing relief from psychotic symptoms without the significant side effects of other medications. It's like finding a more efficient and comfortable camel caravan, offering a smoother journey through the desert of psychosis.

Living with Parkinson's Disease: Navigating the Desert of Psychosis

This research highlights the importance of ongoing research and development of new treatments for [PDP], offering hope for those living with Parkinson's disease. Staying informed, seeking professional guidance, and exploring new treatment options are essential for navigating the desert of Parkinson's disease. Remember, just as a camel needs the right tools and support to journey through the desert, so too do those living with Parkinson's disease need a comprehensive approach to managing their health and well-being.

Dr. Camel's Conclusion

The desert of Parkinson's disease psychosis can be a challenging landscape, but this research offers a glimmer of hope. [Pimavanserin] shows promise as a new treatment option, potentially offering relief from psychotic symptoms without significant side effects. By embracing new possibilities and staying informed about the latest advancements, we can navigate this desert with greater confidence and resilience.

Date :
  1. Date Completed 2010-04-28
  2. Date Revised 2022-04-10
Further Info :

Pubmed ID

19907417

DOI: Digital Object Identifier

PMC3055369

Related Literature

Article Analysis
・Side Effects of pimavanserin
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.